MED13L

Across TCGA pan-cancer cohorts, MED13L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MED13L data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MED13L mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MED13L expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, PDAC, and HNSC are the cancer types where MED13L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	0.949	0.694	.001	59	view →
PDAC	OS	Tertile	All	0.278	0.456	.010	16	view →
HNSC	DFS	Tertile	II,III,IV	0.976	0.851	.026	4	view →
LUAD	OS	Tertile	II,III,IV	0.518	1.000	.020	4	view →
CCRCC	OS	Quartile	II,III,IV	0.536	0.860	.034	2	view →
GBM	DFS	Quartile	All	0.892	0.566	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MED13L–LSCC (OS)

Open the LSCC breakdown →